Immunotherapy Industry, July 2014 Market Reports from Top Publishers

You might be interested in: cancer, therapeutics, medical equipment, more »


 
1-10 of 44 reports for Immunotherapy

Immunotherapy in Oncology Drug Pipeline Update 2014

Immunotherapy in Oncology Drug Pipeline Update 2014

  • $ 3 675
  • Industry report
  • July 2014
  • by Bioseeker

... immunotherapy in oncology drug pipeline update 2014 cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity ...

Immunotherapy in Oncology: Drug Pathway Analyzer 2014

Immunotherapy in Oncology: Drug Pathway Analyzer 2014

  • $ 3 675
  • Industry report
  • July 2014
  • by Bioseeker

... immunotherapy drug-pathway relationship by using up to four different pathway sources and further refine your analysis with up to 20 different pipeline parameters, including parameters such as presence ...

MarketVIEW: allergic immunotherapies

MarketVIEW: allergic immunotherapies

  • $ 4 495
  • Industry report
  • July 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

... immunotherapies methodology: allergic rhinitis prevalence and severity methodology: sensitization to inhaled allergens methodology: treatment inputs methodology: treatment pricing ...

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

  • $ 4 995
  • Industry report
  • June 2014
  • by Firstword Pharma

... Effective and safe products to the market. The future of cancer immunotherapy: kol views bring opportunities into sharp focus highlightsthere are several types of cancer immunotherapy ...

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2014

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2014

  • $ 2 000
  • Industry report
  • May 2014
  • by Global Markets Direct

... Featured news & press releases 41apr 07, 2014: research expands understanding of biomarker for biothera cancer immunotherapy imprime pgg 41appendix 42methodology 42coverage 42 ...

Ablynx NV (ABLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Ablynx NV (ABLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

... With merck serono 24ablynx extends agreement with boehringer ingelheim 25merck enters into licensing agreement with ablynx for cancer immunotherapy 26ablynx enters into licensing agreement ...

Compugen Ltd. (CGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Compugen Ltd. (CGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

... Healthcare for cancer immunotherapies 16compugen enters into licensing agreement with seattle genetics 18bayer schering enters into option licensing agreement with compugen 19equity offering ...

Octapharma AG SWOT Analysis, Strategy, Revenues and Profits

Octapharma AG SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • May 2014
  • by Global Data

... Haematology and immunotherapy, and intensive care and emergency medicine. Octapharma's offers these products under its brands, namely, albuminativ, albunorm, atenativ, aunativ, gammanorm, nanofix, nanotiv ...

ImmunoCellular Therapeutics, Ltd. (IMUC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ImmunoCellular Therapeutics, Ltd. (IMUC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

... S immunotherapies product pipeline comprises lead prduct cand, ict-107, ict-140, ict-121. Ict-107 is being developed for the treatment of glioblastoma multiforme (gbm); ict-140, a dc vaccine designed to treat ...

Lorus Therapeutics Inc. (LOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Lorus Therapeutics Inc. (LOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

... That suppresses tumor growth; lor-500 program, small molecule anticancer agents indicated against multiple cancers; and il-17e, an immunotherapy with antitumor efficacy against several tumor types. The company ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.